Learn about the latest novel genomic and multi-omic approaches in treating Alzheimer’s disease in this Discovery Lecture Series event.
Deep molecular phenotyping and precision medicine in neurodegenerative diseases
Presented by Carlos Cruchaga, scientific director, McDonnell Genomic Institute, Washington University School of Medicine, St. Louis
Tuesday, November 19, 2019
1–2 p.m.
Biodesign B (BDB) auditorium, Tempe campus [map]
This event is free and open to the public. Seating is on a first-come, first-served basis.
About the lecture
More than 30 different loci have been identified for Alzheimer’s disease risk. However, it is difficult to translate these results to the bedside, because in most of the cases the functional variant and gene-driven association is unknown. In other cases, to model the novel genes in cellular and animal modes is challenging due to the small effect size of those genes. By using novel genomic and multi-omic approaches it is possible to identify novel molecular biomarkers and prediction models, identify genes implicated on the disease and novel therapeutic targets.
About the speaker
Carlos Cruchaga is a human genomicist with expertise in multi-omics, informatics and neurodegeneration. He studies the genetic architecture of neurodegenerative diseases with a focus in using human genomic and other omic data to identify and understand the biological processes that lead to Alzheimer’s disease and Parkinson’s disease, frontotemporal dementia and other neurodegenerative processes.
He pioneered the use of next-generation sequencing technology to identify novel functional variants implicated on Alzheimer’s disease and Parkinson’s disease.
Cruchaga is the scientific director of the McDonnell Genome Institute, Washington University. He completed his doctorate in biochemistry and molecular biology from the University of Navarra, Spain.
